First-in-human clinical trial of high-dose sodium copper chlorophyllin: Pharmacology and efficacy as a dual immunomodulatory/antiviral agent
Phytomedicine · 2026
DOI: 10.1016/j.phymed.2025.157689 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Phytomedicine, 2026. Verfasst von Raghavendra S Patwardhan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Biology & Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India; Homi Bhabha National Institute, Training …. Hauptthemen laut MEDLINE: Antiviral Agents, Chlorophyllides, COVID-19 Drug Treatment, Immunomodulating Agents. Die Arbeit nennt 86 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Department of Atomic Energy, Government of India, Bhabha Atomic Research Centre.
Abstract (Originalsprache)
BACKGROUND: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), continues to evolve, resulting in the emergence of novel variants capable of sustaining localized epidemics and global endemicity. Current therapeutic options primarily target viral replication or immune checkpoints independently, highlighting a need for agents with dual antiviral and immunomodulatory activity. Sodium copper chlorophyllin (CHL), a water-soluble chlorophyll derivative with a long-standing record of safe human consumption, exhibits antioxidant, cytoprotective, and immunoregulatory properties, suggesting potential for repurposing against SARS-CoV-2. This study aimed to evaluate the safety, pharmacokinetics, immunomodulatory efficacy, and antiviral potential of CHL in human, in vitro, and in vivo models. METHODS: A first-in-human clinical trial of high-dose CHL was conducted in healthy male subjects, and pharmacokinetics, pharmacodynamics, and safety were evaluated. In silico binding studies with the SARS-CoV-2 Mpro protease and in vitro findings in the Vero2 monkey kidney cell line were performed. The in vivo antiviral efficacy of CHL was studied in SARS-CoV-2-infected golden Syrian hamsters. RESULTS: In a phase I clinical trial, CHL was well tolerated up to 3000 mg and achieved serum concentrations >5 μM in healthy male volunteers. Proteomic profiling revealed that CHL induced biphasic immune modulation. It bound stably to the main proteases of the coronavirus in silico and showed potent antiviral activity in vitro (IC₅₀ < 1 μM). In hamsters, CHL significantly reduced viral load, inflammation, and lung pathology in both prophylactic and therapeutic settings. CONCLUSION: CHL demonstrates a favorable safety profile, immunomodulatory capacity, and antiviral efficacy, supporting its potential as a broad-spectrum agent for COVID-19 management. FUNDING: Department of Atomic Energy, Government of India.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiation Biology & Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India; Homi Bhabha National Institute, Training School Complex, Anushaktinagar, Mumbai 400094, India; Radiobiology & O…
- Translational Health Science and Technology Institute (THSTI), Faridabad 121001, India.
- Homi Bhabha National Institute, Training School Complex, Anushaktinagar, Mumbai 400094, India; Advanced Centre for Treatment, Research & Education in Cancer (ACTREC-TMC), Kharghar 410210, India. Electronic address: vgot…
- Radiation Biology & Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India; Homi Bhabha National Institute, Training School Complex, Anushaktinagar, Mumbai 400094, India.
- Radiation Biology & Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
- ICMR-National Institute of Virology (ICMR-NIV), Pune 411001, India.
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India
- Department of Atomic Energy, Government of India
- Bhabha Atomic Research Centre
- India Ministry of Science & Technology Department of Science and Technology
Zitieren
APA
Patwardhan, R. S., Rizvi, Z. A., Gota, V., Checker, R., Singh, B., Maurya, D. K., Pal, D., Ramani, N., Kumar, B. K., Purohit, V., Mathapati, B. S., Mullick, J., Ghanty, T. K., Gupta, S., Joshi, M., Madki, S., Awasthi, A., Sandur, S. K., & Sharma, D. (2026). First-in-human clinical trial of high-dose sodium copper chlorophyllin: Pharmacology and efficacy as a dual immunomodulatory/antiviral agent. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.157689
Vancouver
Patwardhan RS, Rizvi ZA, Gota V, Checker R, Singh B, Maurya DK, et al. First-in-human clinical trial of high-dose sodium copper chlorophyllin: Pharmacology and efficacy as a dual immunomodulatory/antiviral agent. Phytomedicine. 2026. doi:10.1016/j.phymed.2025.157689
BibTeX
@article{Patwardhan2026,
author = {Patwardhan, Raghavendra S and Rizvi, Zaigham Abbas and Gota, Vikram and Checker, Rahul and Singh, Babita and Maurya, Dharmendra K and Pal, Debojyoti and Ramani, Neha and Kumar, Binita K and Purohit, Vaitashi and Mathapati, Basavaraj S and Mullick, Jayati and Ghanty, Tapan K and Gupta, Sudeep and Joshi, Mahendra and Madki, Shivkumar and Awasthi, Amit and Sandur, Santosh K and Sharma, Deepak},
title = {First-in-human clinical trial of high-dose sodium copper chlorophyllin: Pharmacology and efficacy as a dual immunomodulatory/antiviral agent},
journal = {Phytomedicine},
year = {2026},
doi = {10.1016/j.phymed.2025.157689}
}
EUVIMED